Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

Article summary

Cognition Therapeutics has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the design of a Phase 3 registrational study for its lead candidate, zervimesine (CT1812), in patients with dementia with Lewy bodies (DLB).